TCBPY
TC Biopharm (Holdings) Plc
Price Chart
Latest Quote
$0.01
-0.00 (-8.33%)
Current Price
| Previous Close | $0.01 |
| Open | $0.04 |
| Day High | $0.04 |
| Day Low | $0.02 |
| Volume | 31,200 |
Stock Information
Note: Financial values converted from GBP to USD
| Shares Outstanding | 2.10M |
| Total Debt | $2.00M |
| Cash Equivalents | $1.62M |
| Net Income | $-16.22M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $12K |
| EPS (TTM) | $-130.36 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $46.55M |
| Income | $-16.22M |
| Book/sh | $6.38 |
| Cash/sh | $0.58 |
| Employees | 39 |
Financial Ratios
| Quick Ratio | 0.45 |
| Current Ratio | 1.39 |
| Debt/Eq | 49.82 |
Returns & Margins
| ROA | -92.84% |
| ROE | -426.84% |
Ownership
| Institutional Ownership | 0.08% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | 0.00 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.01 |
| SMA200 | $0.11 |
| RSI | nan |
| Shares Float | 8.41B |
| Short Float | 10.22% |
| Short Ratio | 0.11 |
| Volatility | 48.18 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | -89.22% |
| 6 Months | -96.56% |
| YTD | -94.50% |
| Year | -98.17% |
| 3 Years | -100.00% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $0.01 | 0 |
| 2026-06-03 | $0.01 | 0 |
| 2026-06-02 | $0.01 | 0 |
| 2026-06-01 | $0.01 | 0 |
| 2026-05-29 | $0.01 | 0 |
| 2026-05-28 | $0.01 | 0 |
| 2026-05-27 | $0.01 | 0 |
| 2026-05-26 | $0.01 | 0 |
| 2026-05-22 | $0.01 | 0 |
| 2026-05-21 | $0.01 | 0 |
| 2026-05-20 | $0.01 | 0 |
| 2026-05-19 | $0.01 | 0 |
| 2026-05-18 | $0.01 | 0 |
| 2026-05-15 | $0.01 | 0 |
| 2026-05-14 | $0.01 | 0 |
| 2026-05-13 | $0.01 | 0 |
| 2026-05-12 | $0.01 | 0 |
| 2026-05-11 | $0.01 | 0 |
| 2026-05-08 | $0.01 | 0 |
| 2026-05-07 | $0.01 | 0 |
| 2026-05-06 | $0.01 | 0 |
| 2026-05-05 | $0.01 | 0 |
About TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, develops immunotherapy products based on its allogeneic gamma delta T cell platform in the United States. Its product pipeline comprises OmnImmune (TCB002), an allogeneic unmodified gamma-delta T cell therapy product which is in phase 2/3 clinical trial for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections, as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
đ° Latest News
No news articles available at the moment. Check back later for updates on TCBPY.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $3,844,532 | $1,978,659 |
| Operating Revenue | $0 | $0 | $3,844,532 | $1,978,659 |
| Expenses | ||||
| Interest Expense | $0 | $83,025 | $6,753,231 | $3,438,548 |
| Total Expenses | $12,767,670 | $14,239,323 | $15,928,529 | $9,259,302 |
| Other Income Expense | $-38,331 | $7,326,666 | $15,803,627 | $-4,264,309 |
| Other Non Operating Income Expenses | $-51,768 | $-80,070 | $-120,974 | - |
| Net Non Operating Interest Income Expense | $0 | $-83,025 | $-6,753,231 | $-3,438,515 |
| Interest Expense Non Operating | $0 | $83,025 | $6,753,231 | $3,438,548 |
| Operating Expense | $12,767,670 | $14,239,323 | $15,928,529 | $9,259,302 |
| General And Administrative Expense | $7,400,624 | $6,467,932 | $8,336,059 | $3,108,794 |
| Other Operating Expenses | - | - | - | $-6,381 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-12,154,030 | $-5,906,953 | $-1,313,601 | $-13,575,925 |
| Net Interest Income | $0 | $-83,025 | $-6,753,231 | $-3,438,515 |
| Normalized Income | $-12,166,783 | $-12,160,988 | $-14,212,528 | $-9,712,204 |
| Net Income From Continuing And Discontinued Operation | $-12,154,030 | $-5,906,953 | $-1,313,601 | $-13,575,925 |
| Total Operating Income As Reported | $-12,767,670 | $-14,239,323 | $-12,083,997 | - |
| Net Income Common Stockholders | $-12,154,030 | $-5,906,953 | $-1,313,601 | $-13,575,925 |
| Net Income | $-12,154,030 | $-5,906,953 | $-1,313,601 | $-13,575,925 |
| Net Income Including Noncontrolling Interests | $-12,154,030 | $-5,906,953 | $-1,313,601 | $-13,575,925 |
| Net Income Continuous Operations | $-12,154,030 | $-5,906,953 | $-1,313,601 | $-13,575,925 |
| Pretax Income | $-12,806,001 | $-6,995,682 | $-3,033,601 | $-14,983,467 |
| Special Income Charges | $0 | $-645,845 | $-140,344 | $0 |
| Operating Income | $-12,767,670 | $-14,239,323 | $-12,083,997 | $-7,280,643 |
| Interest Income | - | - | $2,208 | $33 |
| Interest Income Non Operating | - | - | $2,208 | $33 |
| Per Share | ||||
| Diluted EPS | - | $-3072.00 | $-6112.00 | $-111278.07 |
| Basic EPS | - | $-3072.00 | $-6112.00 | $-111278.07 |
| Other | ||||
| Tax Effect Of Unusual Items | $684 | $1,152,701 | $3,025,674 | $-400,588 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,385,169 | $-13,686,385 | $-11,435,375 | $-6,255,552 |
| Total Unusual Items | $13,437 | $7,406,736 | $15,924,601 | $-4,264,309 |
| Total Unusual Items Excluding Goodwill | $13,437 | $7,406,736 | $15,924,601 | $-4,264,309 |
| Reconciled Depreciation | $434,269 | $633,008 | $769,596 | $1,025,058 |
| EBITDA (Bullshit earnings) | $-12,371,732 | $-6,279,649 | $4,489,226 | $-10,519,861 |
| EBIT | $-12,806,001 | $-6,912,657 | $3,719,630 | $-11,544,919 |
| Diluted NI Availto Com Stockholders | $-12,154,030 | $-5,906,953 | $-1,313,601 | $-13,575,925 |
| Tax Provision | $-651,971 | $-1,088,729 | $-1,720,000 | $-1,407,542 |
| Gain On Sale Of Security | $13,437 | $8,052,581 | $16,064,945 | $-4,264,309 |
| Research And Development | $5,367,046 | $7,771,391 | $7,592,470 | $6,156,889 |
| Selling General And Administration | $7,400,624 | $6,467,932 | $8,336,059 | $3,108,794 |
| Other Gand A | $7,400,624 | $6,467,932 | $8,336,059 | $3,108,794 |
| Diluted Average Shares | - | $1,931 | $545 | $122 |
| Basic Average Shares | - | $1,931 | $545 | $122 |
| Other Special Charges | - | $645,845 | $140,344 | - |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,543,361 | $2,070,060 | $-221,751 | $-17,042,626 |
| Total Assets | $8,328,537 | $8,931,664 | $11,291,977 | $8,023,596 |
| Total Non Current Assets | $2,553,886 | $3,230,737 | $3,844,461 | $4,167,756 |
| Goodwill And Other Intangible Assets | $466,262 | $615,170 | $553,016 | $483,577 |
| Other Intangible Assets | $466,262 | $615,170 | $553,016 | $483,577 |
| Current Assets | $5,774,651 | $5,700,927 | $7,447,516 | $3,855,840 |
| Current Deferred Assets | $3,031,989 | $1,177,500 | $0 | - |
| Prepaid Assets | $786,803 | $829,999 | $836,137 | $811,303 |
| Receivables | $740,219 | $1,230,819 | $1,803,319 | $1,477,849 |
| Other Receivables | $7,837 | $51,584 | $56,264 | - |
| Taxes Receivable | $732,382 | $1,179,235 | $1,747,055 | $1,477,849 |
| Cash Cash Equivalents And Short Term Investments | $1,215,640 | $2,462,609 | $4,808,060 | $1,566,688 |
| Cash And Cash Equivalents | $1,215,640 | $2,462,609 | $4,808,060 | $1,566,688 |
| Debt | ||||
| Total Debt | $1,499,483 | $1,801,157 | $2,778,352 | $9,708,843 |
| Long Term Debt And Capital Lease Obligation | $1,171,019 | $1,495,833 | $1,796,835 | $2,136,875 |
| Current Debt And Capital Lease Obligation | $328,464 | $305,324 | $981,517 | $7,571,968 |
| Current Debt | - | - | $653,484 | $6,806,210 |
| Other Current Borrowings | - | - | $653,484 | $6,806,210 |
| Net Debt | - | - | - | $5,239,522 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,318,914 | $6,246,434 | $10,960,712 | $24,582,645 |
| Total Non Current Liabilities Net Minority Interest | $1,171,019 | $1,495,833 | $1,796,835 | $4,002,748 |
| Current Liabilities | $4,147,895 | $4,750,601 | $9,163,877 | $20,579,897 |
| Payables And Accrued Expenses | $3,819,431 | $4,431,840 | $2,159,058 | $4,103,615 |
| Payables | $1,629,988 | $2,024,921 | $1,214,154 | $1,773,033 |
| Other Payable | $488 | $38,613 | $38,323 | $39,436 |
| Total Tax Payable | $236,175 | $139,029 | $293,467 | $311,204 |
| Accounts Payable | $1,393,325 | $1,847,279 | $882,364 | $1,422,393 |
| Other Current Liabilities | - | $13,437 | $6,023,302 | $6,925,654 |
| Non Current Deferred Liabilities | - | - | $0 | $1,865,873 |
| Current Deferred Liabilities | - | - | $0 | $1,978,660 |
| Equity | ||||
| Common Stock Equity | $3,009,623 | $2,685,230 | $331,265 | $-16,559,049 |
| Total Equity Gross Minority Interest | $3,009,623 | $2,685,230 | $331,265 | $-16,559,049 |
| Stockholders Equity | $3,009,623 | $2,685,230 | $331,265 | $-16,559,049 |
| Other Equity Interest | $397,398 | $397,398 | $397,398 | - |
| Retained Earnings | $-52,559,029 | $-40,404,999 | $-33,374,796 | $-33,465,282 |
| Gains Losses Not Affecting Retained Earnings | - | - | $16,710,757 | $16,710,757 |
| Other Equity Adjustments | - | - | $16,710,757 | $16,710,757 |
| Other | ||||
| Ordinary Shares Number | $2,489,348,051 | $25,712,610 | $2,181,141 | $488,690 |
| Share Issued | $2,489,348,051 | $25,712,610 | $2,181,141 | $488,690 |
| Tangible Book Value | $2,543,361 | $2,070,060 | $-221,751 | $-17,042,626 |
| Invested Capital | $3,009,623 | $2,685,230 | $984,749 | $-9,752,839 |
| Working Capital | $1,626,756 | $950,326 | $-1,716,361 | $-16,724,057 |
| Capital Lease Obligations | $1,499,483 | $1,801,157 | $2,124,868 | $2,902,633 |
| Total Capitalization | $3,009,623 | $2,685,230 | $331,265 | $-16,559,049 |
| Additional Paid In Capital | $54,916,172 | $42,690,774 | $33,308,568 | $0 |
| Capital Stock | $255,082 | $2,057 | $95 | $195,476 |
| Common Stock | $255,082 | $2,057 | $95 | $195,476 |
| Long Term Capital Lease Obligation | $1,171,019 | $1,495,833 | $1,796,835 | $2,136,875 |
| Current Capital Lease Obligation | $328,464 | $305,324 | $328,033 | $765,758 |
| Current Accrued Expenses | $2,189,443 | $2,406,919 | $944,904 | $2,330,582 |
| Net PPE | $2,087,624 | $2,615,567 | $3,291,445 | $3,684,179 |
| Accumulated Depreciation | $-4,540,969 | $-4,157,382 | $-3,560,656 | $-3,010,486 |
| Gross PPE | $6,628,593 | $6,772,949 | $6,852,101 | $6,694,665 |
| Machinery Furniture Equipment | $5,495,777 | $5,432,180 | $5,321,827 | $5,309,141 |
| Buildings And Improvements | $1,132,816 | $1,340,769 | $1,530,274 | $1,379,360 |
| Properties | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | - | - | $0 | $1,865,873 |
| Current Deferred Revenue | - | - | $0 | $1,978,660 |
| Other Properties | - | - | $2,056 | $6,164 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,659,802 | $-10,753,659 | $-15,657,494 | $-5,724,246 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,567,288 | $-10,544,870 | $-15,292,297 | $-5,581,022 |
| Cash Flow From Continuing Operating Activities | $-12,567,288 | $-10,544,870 | $-15,292,297 | $-5,581,022 |
| Operating Gains Losses | $38,364 | $-7,972,511 | $-15,935,325 | $4,246,528 |
| Investing Activities | ||||
| Capital Expenditure | $-92,514 | $-208,789 | $-365,197 | $-143,224 |
| Investing Cash Flow | $-92,514 | $-208,789 | $-310,197 | $-143,224 |
| Cash Flow From Continuing Investing Activities | $-92,514 | $-208,789 | $-310,197 | $-143,224 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $819,635 | $4,186,862 | $3,369,877 | $285,108 |
| Financing Cash Flow | $11,464,634 | $8,520,376 | $18,653,214 | $6,525,138 |
| Cash Flow From Continuing Financing Activities | $11,464,634 | $8,520,376 | $18,653,214 | $6,525,138 |
| Net Other Financing Charges | $-439,448 | $-793,746 | $-908,602 | $-21,160 |
| Net Common Stock Issuance | $819,635 | $4,186,862 | $3,369,877 | $285,108 |
| Common Stock Issuance | $819,635 | $4,186,862 | $3,369,877 | $285,108 |
| Other | ||||
| Repayment Of Debt | $0 | $0 | $-2,632,324 | $-122,469 |
| Issuance Of Debt | $0 | $0 | $18,110 | $6,383,659 |
| End Cash Position | $1,215,640 | $2,462,609 | $4,808,060 | $1,566,688 |
| Beginning Cash Position | $2,462,609 | $4,808,060 | $1,566,688 | $748,015 |
| Effect Of Exchange Rate Changes | $-51,801 | $-112,168 | $190,652 | $17,781 |
| Changes In Cash | $-1,195,168 | $-2,233,283 | $3,050,720 | $800,892 |
| Proceeds From Stock Option Exercised | $11,084,447 | $5,127,260 | $18,806,153 | $0 |
| Net Issuance Payments Of Debt | $0 | $0 | $-2,614,214 | $6,261,190 |
| Net Long Term Debt Issuance | $0 | $0 | $-2,614,214 | $6,261,190 |
| Long Term Debt Payments | $0 | $0 | $-2,632,324 | $-122,469 |
| Long Term Debt Issuance | $0 | $0 | $18,110 | $6,383,659 |
| Net Intangibles Purchase And Sale | $-28,914 | $-98,436 | $-124,485 | $-123,191 |
| Purchase Of Intangibles | $-28,914 | $-98,436 | $-124,485 | $-123,191 |
| Net PPE Purchase And Sale | $-63,600 | $-110,353 | $-185,712 | $-20,033 |
| Sale Of PPE | $0 | $0 | $55,000 | $0 |
| Purchase Of PPE | $-63,600 | $-110,353 | $-240,712 | $-20,033 |
| Change In Working Capital | $-2,026,818 | $1,539,714 | $-6,704,967 | $-232,079 |
| Change In Other Current Liabilities | $-301,674 | $-323,711 | $-762,150 | - |
| Change In Other Current Assets | $207,953 | $189,505 | $196,577 | - |
| Change In Payables And Accrued Expense | $-612,409 | $2,272,782 | $-1,944,557 | $2,338,197 |
| Change In Prepaid Assets | $-1,712,310 | $-1,275,269 | $-37,503 | - |
| Change In Receivables | $391,622 | $676,407 | $-312,801 | $-591,617 |
| Stock Based Compensation | $1,013,788 | $444,459 | $1,123,250 | $0 |
| Asset Impairment Charge | $127,139 | $0 | $0 | - |
| Depreciation Amortization Depletion | $434,269 | $633,008 | $769,596 | $1,025,058 |
| Depreciation And Amortization | $434,269 | $633,008 | $769,596 | $1,025,058 |
| Amortization Cash Flow | $50,682 | $36,282 | $55,046 | $63,451 |
| Amortization Of Intangibles | $50,682 | $36,282 | $55,046 | $63,451 |
| Depreciation | $383,587 | $596,726 | $714,550 | $961,607 |
| Gain Loss On Investment Securities | $-13,437 | $-8,052,581 | $-16,064,945 | $4,181,545 |
| Net Foreign Currency Exchange Gain Loss | $51,801 | $80,070 | $120,974 | $64,983 |
| Gain Loss On Sale Of PPE | $0 | $0 | $8,646 | $0 |
| Net Income From Continuing Operations | $-12,154,030 | $-5,906,953 | $-1,313,601 | $-14,983,467 |
| Other Non Cash Items | - | $717,413 | $6,768,750 | $3,438,515 |
| Taxes Refund Paid | - | - | $1,407,199 | $1,179,043 |
| Interest Received Cfo | - | - | $2,208 | $33 |
| Interest Paid Cfo | - | - | $-289,912 | $-254,653 |
| Change In Other Working Capital | - | - | $-3,844,533 | $-1,978,659 |
| Change In Payable | - | - | $-1,944,557 | $2,338,197 |
Fetched: 2026-02-02